TrialHaematologica2018

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.

Eric Van Den Neste et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.